SCHEMBL720308

SCHEMBL720308

CCCCCCCCC(CO)(OCC)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.36
CNR2 P34972 2/20 0.36
TNNC1 P63316 5/20 0.36
SIGMAR1 Q99720 2/20 0.36
S1PR1 P21453 2/20 0.36
SGPL1 O95470 1/20 0.36
S1PR4 O95977 1/20 0.36
GPR183 P32249 1/20 0.36
CERS2 Q96G23 1/20 0.36
S1PR3 Q99500 1/20 0.36
S1PR5 Q9H228 1/20 0.36
GAA P10253 1/20 0.36
SPHK2 Q9NRA0 1/20 0.36
SCN5A Q14524 3/20 0.36
SCN9A Q15858 3/20 0.36
EBP Q15125 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10596867 0.86 NPC1 (0.36) CNR1CNR2SIGMAR1GAASCN5A
SCHEMBL27983297 0.84 KIF11 (0.38) SIGMAR1
SCHEMBL8990316 0.84 ALDH1A1 (0.39)
SCHEMBL9242864 0.81 ALDH1A1 (0.42) CNR1CNR2SIGMAR1GAASCN5A
SCHEMBL30865104 0.81 SIGMAR1 (0.40) CNR1CNR2SIGMAR1GAASCN5A
SCHEMBL3807681 0.81 SIGMAR1 (0.40) CNR1CNR2SIGMAR1GAASCN5A
SCHEMBL720310 0.79 SIGMAR1 (0.41) CNR1CNR2SIGMAR1GAASCN5A
SCHEMBL28944305 0.78 SIGMAR1 (0.38) CNR1CNR2SIGMAR1GAASCN5A
SCHEMBL9168403 0.78 LTA4H (0.38) CNR1CNR2SIGMAR1GAAEBP
SCHEMBL3972776 0.77 SIGMAR1 (0.37) CNR1CNR2SIGMAR1GAASCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180327827-A1 METHOD OF ISOLATING NUCLEIC ACID SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (KR) 2018-11-15 US disclosed
EP-2438166-B1 METHOD FOR PREPARING PROTEIN, DNA, AND RNA FROM CELL CANON KK (JP) 2015-11-11 EP disclosed
US-9169480-B2 Method for preparing protein, DNA, and RNA from cell CANON KABUSHIKI KAISHA (JP) 2015-10-27 US disclosed
EP-2438166-A1 METHOD FOR PREPARING PROTEIN, DNA, AND RNA FROM CELL Canon Kabushiki Kaisha (JP) 2012-04-11 EP disclosed
US-20120053329-A1 METHOD FOR PREPARING PROTEIN, DNA, AND RNA FROM CELL CANON KABUSHIKI KAISHA (JP) 2012-03-01 US disclosed
WO-2010140598-A1 METHOD FOR PREPARING PROTEIN, DNA, AND RNA FROM CELL CANON KABUSHIKI KAISHA (JP) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053329-A1 METHOD FOR PREPARING PROTEIN, DNA, AND RNA FROM CELL DDX21, HNRNPR, NXF1 CNR1 4261/4885CNR2 4700/4885TNNC1 1162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.